Genzyme/Xenova
Executive Summary
Firms announce three-year drug discovery collaboration April 8 that will focus on low molecular weight pharmaceutical agents for treating "several inflammatory diseases," in particular respiratory diseases. U.K. firm Xenova will have exclusive European rights to any resulting compounds in Europe, and Genzyme will have rights "in the rest of the world".